#ASCO14 - Poster: Enzalutamide monotherapy: 1-year extended follow-up of a Phase 2 study in hormone-naive prostate cancer patients

CHICAGO, IL USA (UroToday.com) - Presented by Bertrand Tombal,¹ Michael Borre,² Per Rathenborg,³ Patrick Werbrouck,⁴ Hendrick Van Poppel,⁵ Axel Heidenreich,⁶ Peter Iversen,⁷ Johan Braeckman,⁸ Jiri Heracek,⁹ Edwina Baskin-Bey,¹⁰ Taoufik Ouatas,¹⁰ Frank Perabo,¹¹ De Phung,¹⁰ Mohammad Hirmand,¹² Matthew R. Smith¹³ at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

¹Cliniques Universitaires Saint-Luc, Brussels, Belgium
²Aarhus University Hospital, Aarhus, Denmark
³Herlev University Hospital, Herlev, Denmark
⁴AZ Groeninge Kortrijk, Kortrijk, Belgium
⁵UZ Leuven, Leuven, Belgium
⁶Klinik und Poliklinik für Urologie, RWTH University Aachen, Aachen, Germany
⁷Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
⁸UZ Brussel, Brussels, Belgium
⁹Univerzita Karlova v Praze, Prague, Czech Republic
¹⁰Astellas Pharma Global Development, Leiden, the Netherlands
¹¹Astellas Pharma Global Development, Northbrook, IL USA
¹²Medivation, Inc., San Francisco, CA USA
¹³Massachusetts General Hospital Cancer Center, Boston, MA, USA